Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Eupraxia Pharmaceuticals Inc (EPRX)

Eupraxia Pharmaceuticals Inc (EPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results GlobeNewswire - Tue May 12, 4:00PM CDT

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week GlobeNewswire - Wed May 6, 6:00AM CDT

EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) GlobeNewswire - Tue May 5, 6:00AM CDT

EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer GlobeNewswire - Fri May 1, 4:05PM CDT

VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting GlobeNewswire - Wed Apr 22, 6:00AM CDT

VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis  GlobeNewswire - Tue Apr 21, 6:00AM CDT

This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia’s RESOLVE trial.  At 36 weeks, patients in Cohort...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire - Mon Apr 13, 7:00AM CDT

VICTORIA, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis GlobeNewswire - Tue Mar 17, 6:00AM CDT

For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data is important because it is...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results GlobeNewswire - Thu Mar 12, 8:03PM CDT

VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option GlobeNewswire - Fri Feb 20, 2:10PM CST

VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 7.10 (+2.31%)
EPRX.TO : 10.24 (+5.57%)

Barchart Exclusives

Berkshire Hathaway Buys Macy’s After 60 Years Away From Department Stores. M Stock Offers Real Estate, Dividends, and an Interesting Twist. Barchart - 29 minutes ago
Berkshire Hathaway’s unexpected return to the department store sector with a new stake in Macy’s suggests it may see overlooked value in the retailer. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.